Use of substituted 8-Perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-

1. A method of treating a disease in a patient, said disease selected from the group consisting of vascular dementia; acute stroke, traumatic injury; cerebrovascular accident, brain cord trauma, spinal cord trauma; peripheral neuropathy; retinopathy, glaucoma, alopecia, Pick's disease, progressive supranuclear palsy, age related macular degeneration, breast cancer and thyroid cancer, comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

wherein:

X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C 1-2 alkyl group and a hydrogen atom;

Y represents a bond, a carbonyl group, a methylene group optionally substituted by one or two groups chosen from a C 1 - 6 alkyl group, a hydroxyl group, a C 1-4 alkoxy group, a C 1-2 perhalogenated alkyl group or an amino group;

R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the rings being optionally substituted by a C 1-4 alkyl group, a C 1-4 alkoxy group, or a halogen atom;

R2 represents a phenyl group or a naphthalene ring; the phenyl group and naphthalene ring being optionally substituted by 1 to 4 substituents selected from a C 1-6 alkyl group, a phenyl group, a methylenedioxy group, a halogen atom, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a hydroxyl group, a C 1-4 alkoxy group, a nitro, a cyano, an amino, a C 1-5 monoalkylamino group or a C 2-10 dialkylamino group;

R3 represents a hydrogen atom, or a C 1-6 alkyl group

R4 represents a C 1-2 perhalogenated alkyl group or a C 1-3 halogenated alkyl group;

R5 represents a hydrogen, a C 1-6 alkyl group or a halogen atom;

n represents 0 to 3; and p+q=0 to 3.

2. The method according to claim 1 , wherein R4 represents a C 1-2 perhalogenated alkyl group.

3. The method according to claim 1 , wherein:

R1 represents an unsubstituted 4-pyridine ring or 4-pyrimidine ring;

R2 represents a phenyl group being optionally substituted by 1 to 4 substituents selected from a C 1-3 alkyl group, a phenyl group, a halogen atom, a hydroxyl group, a cyano or a C 1-2 alkoxy group or alternatively R2 represents a phenyl group being optionally substituted by 1 to 4 substituents selected from a C 1-3 alkyl group, a halogen atom, a hydroxyl group or a C 1-2 alkoxy group;

R3 represents a hydrogen atom;

R4 represents a trifluoromethyl group;

R5 represents a hydrogen or fluorine atom or alternatively R5 represents a hydrogen atom;

X represents two hydrogen atoms;

Y represents a carbonyl group or a methylene group optionally substituted by a hydroxyl group;

n, p, and q represent 0, 2 and 0, respectively.

4. The method according to claim 2 , wherein:

R1 represents an unsubstituted 4-pyridine ring or 4-pyrimidine ring;

R2 represents a phenyl group being optionally substituted by 1 to 4 substituents selected from a C 1-3 alkyl group, a phenyl group, a halogen atom, a hydroxyl group, a cyano or a C 1-2 alkoxy group or alternatively R2 represents a phenyl group being optionally substituted by 1 to 4 substituents selected from a C 1-3 alkyl group, a halogen atom, a hydroxyl group or a C 1-2 alkoxy group;

R3 represents a hydrogen atom;

R4 represents a trifluoromethyl group;

R5 represents a hydrogen or fluorine atom or alternatively R5 represents a hydrogen atom;

X represents two hydrogen atoms;

Y represents a carbonyl group or a methylene group optionally substituted by a hydroxyl group;

n, p, and q represent 0, 2 and 0, respectively.

5. The method according to claim 1 , wherein compound of formula (i) is selected from the group consisting of:

9-(2-Oxo-2-phenyl-ethyl)-2-(4-pyridinyl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

9-[(2S)-2-Hydroxy-2-phenyl-ethyl]-2-(4-pyridinyl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

9-[2-(3-Bromo-phenyl)-2-oxo-ethyl]-2-(4-pyridinyl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

9-[2-(3-Bromo-phenyl)-2-hydroxy-ethyl]-2-(4-pyridinyl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

9-[2-Oxo-2-phenyl-ethyl]-2-(4-pyrimidinyl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

(−)-9-(2-Oxo-2-phenyl-ethyl)-2-(4-pyridinyl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

(+)-9-(2-Oxo-2-phenyl-ethyl)-2-(4-pyridinyl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

(+)-9-[2-Oxo-2-phenyl-ethyl]-2-(4-pyrimidinyl)-8-(trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

(−)-9-[2-Oxo-2-phenyl-ethyl]-2-(4-pyrimidinyl)-8-(trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

3-Fluoro-9-(2-oxo-2-phenylethyl)-2-pyridin-4-yl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

9-(Phenylmethyl)-2-pyrimidin-4-yl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

9-(2-Phenylethyl)-2-pyrimidin-4-yl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

9-[2-(3-Bromophenyl)-2-oxoethyl]-2-pyrimidin-4-yl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

9-[2-(3-Fluorophenyl)-2-oxoethyl]-2-pyrimidin-4-yl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

9-[2-(4-Methylphenyl)-2-oxoethyl]-2-pyrimidin-4-yl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

9-[2-(4-Fluorophenyl)-2-oxoethyl]-2-pyrimidin-4-yl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

9-[2-(4-Cyanophenyl)-2-oxoethyl]-2-pyrimidin-4-yl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

9-(2-biphenyl-4-yl-2-oxoethyl)-2-pyrimidin-4-yl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one;

or a salt thereof, or a solvate thereof or a hydrate thereof.

6. The method according to claim 1 , wherein the disease is vascular dementia.

7. The method according to claim 1 , wherein the disease is acute stroke.

8. The method according to claim 1 , wherein the disease is traumatic injury.

9. The method according to claim 1 , wherein the disease is cerebrovascular accident.

10. The method according to claim 1 , wherein the disease is brain cord trauma.

11. The method according to claim 1 , wherein the disease is spinal cord trauma.

12. The method according to claim 1 , wherein the disease is peripheral neuropathy.

13. The method according to claim 1 , wherein the disease is retinopathy.

14. The method according to claim 1 , wherein the disease is glaucoma.

15. The method according to claim 1 , wherein the disease is alopecia.

16. The method according to claim 1 , wherein the disease is Pick's disease.

17. The method according to claim 1 , wherein the disease is progressive supranuclear palsy.

18. The method according to claim 1 , wherein the disease is age related macular degeneration.

19. The method according to claim 1 , wherein the disease is breast cancer.

20. The method according to claim 1 , wherein the disease is thyroid cancer.